Carbamazepine-Danazol Drug Interaction

In: Therapeutic Drug Monitoring · 1986 · vol. 8(4) , pp. 387–392 · doi:10.1097/00007691-198612000-00001 · PMID:3824425 · W2035876416
article OA: closed CC0 ⤵ 3 in-corpus citations
View on OpenAlex View on PubMed View at publisher
AI-generated summary by claude@2026-06, 2026-06-11

Danazol was found to inhibit carbamazepine metabolism by blocking the epoxide-trans-diol pathway, increasing carbamazepine half-life and plasma concentrations by 50-100%.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Carbamazepine (CBZ) labeled with 15N was used to investigate the mechanism of its pharmacokinetic interaction with the antiestrogenic steroid danazol during treatment of a patient with epilepsy. Danazol led to a pronounced inhibition of CBZ metabolism. During danazol coadministration, CBZ elimination half-life increased from a pretreatment value of 11 to 24.3 h. Carbamazepine plasma clearance decreased from 57.7 to 23.2 ml/h/kg. Kinetic analysis of the plasma concentration-time curves and urinary excretion of [15N]trans-CBZ-diol revealed that danazol inhibited the epoxide-trans-diol pathway of carbamazepine metabolism. Observations in five other female patients confirm that the steady-state plasma concentrations of UCBZ increase between 50 and 100% during coadministration of danazol.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (3)

Cited by (3)

Source provenance

openalex
last seen: 2026-05-10T10:37:44.503657+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK